Background: Before 2011, pegylated interferon plus ribavirin was the standard therapy for
chronic hepatitis C. Interferon-free direct-acting antiviral agents were then approved …

ContextApproximately 2.7 million US individuals are chronically infected with the hepatitis C
virus (HCV). As public health campaigns are pursued, a growing number of treatment …

Viral hepatitis is a major public health problem affecting millions of people worldwide. Long‐
term consequences are the development of liver cirrhosis and hepatocellular carcinoma …

OBJECTIVE: To assess the effectiveness of treatment for hepatitis C virus (HCV) infection in
low-and middle-income countries and identify factors associated with successful outcomes …

Objectives: This study assesses whether pegylated interferon and ribavirin is cost-effective
compared with no antiviral treatment provided in routine clinical practice, for different patient …

OBJECTIVES: To determine whether combined therapy with interferon-alpha and ribavirin
was more effective and cost-effective than no treatment for patients with mild chronic …

Hepatitis C is an important cause of chronic liver disease worldwide with an estimated 170
million people infected. Hepatitis C virus (HCV)-infected patients are physically and mentally …

Chronic hepatitis C is associated with substantial morbidity and mortality and poses a
considerable socioeconomic burden. Improved treatment regimens, including the standard …

Background Recently developed interferon-and ribavirin-free regimens to treat hepatitis C
virus infection (HCV) have low side effect profile accompanied by high efficacy. Aim To …

Chronic hepatitis C virus (HCV) infection increases all-cause mortality, rates of cirrhosis,
hepatocellular carcinoma, liver transplantation and overall health care utilization. Morbidity …